A little more recent commentary
New AD-214 partnering leads – three top 20 pharma companies under confidentiality agreement Across the two weeks of partnering events, the Company participated in 20 meetings related to AD-214. With many partners already in AdAlta’s out-licensing pipeline waiting for the results of the ongoing Phase I extension study, the Company was pleased to field several new licensing enquiries. Of particular note were: • A new confidentiality agreement request from a top 20 global pharmaceutical, the third such company actively progressing detailed evaluation of AD-214.
• Approximately half the discussions were new interest from investors exploring co-developing/asset financing of Phase II clinical trials of AD-214. AD-214 Phase I extension study on track A key milestone for AD-214 several partnering discussions is completion of the Phase I extension study testing the safety and tolerability of AD-214 at planned Phase II doses. All participants have now successfully received all doses, with final results on track for delivery by end of February 2024.
Add to My Watchlist
What is My Watchlist?
